Tizetatug Rezetecan

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 19:37:27 GMT 2025` Edited by `admin` on `Wed Apr 02 19:37:27 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type	IGG1\|KAPPA
Sequence Origin	HUMANIZED MOUSE
Sequence Type	COMPLETE
Record UNII	UJR3SD8NLS
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Tizetatug Rezetecan

Official Name

English

H-gamma1 heavy chain humanized (1-451) [VH (Homo sapiens IGHV1-69*02 (88.8%) -(IGHD) -IGHJ4*01 (93.3%), CDR-IMGT [8.8.14] (26-35.51-58.97-110)) (1-121) -Homo sapiens IGHG1*01 (100%) G1m17,1 CH1 K120, CH3 D12, L14 (CH1 K120 (218) (122-219), hinge 1-15 (22

Preferred Name

English

immunoglobulin G1-kappa, anti-[Homo sapiens TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epit

Common Name

English

Immunoglobulin G1, anti-(human tumor-associated calcium signal transducer 2) (human-Mus musculus monoclonal HRP02606 ?1-chain), human-Mus musculus monoclonal HRP02606 ?-chain, dimer, reduced, tetrakis(thioether) with (2S)-N-[6-(3-mercapto-2,5-dioxo-1-pyr

Common Name

English

tizetatug rezetecan [INN]

Common Name

English

Code System Code Type Description

SMS_ID

300000056834

Created by admin on Wed Apr 02 19:37:27 GMT 2025 , Edited by admin on Wed Apr 02 19:37:27 GMT 2025

PRIMARY

CAS

2938864-88-9

Created by admin on Wed Apr 02 19:37:27 GMT 2025 , Edited by admin on Wed Apr 02 19:37:27 GMT 2025

PRIMARY

NCI_THESAURUS

C211811

Created by admin on Wed Apr 02 19:37:27 GMT 2025 , Edited by admin on Wed Apr 02 19:37:27 GMT 2025

PRIMARY

FDA UNII

UJR3SD8NLS

Created by admin on Wed Apr 02 19:37:27 GMT 2025 , Edited by admin on Wed Apr 02 19:37:27 GMT 2025

PRIMARY

INN

13287

Created by admin on Wed Apr 02 19:37:27 GMT 2025 , Edited by admin on Wed Apr 02 19:37:27 GMT 2025

PRIMARY

From	To
1_22	1_96
2_22	2_96
2_148	2_204
2_224	4_214
2_265	2_325
1_148	1_204
2_371	2_429
3_23	3_88
3_134	3_194
4_23	4_88
4_134	4_194
1_224	3_214
1_230	2_230
1_233	2_233
1_265	1_325
1_371	1_429

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_301
N	2_301

Related Record Type Details


					GM1W90Y88M

TUMOR-ASSOCIATED CALCIUM SIGNAL TRANSDUCER 2

TARGET->LIGAND

Amount:


					PCX6SM5JNT

Tizetatug

PARENT -> CONJUGATE

Amount:


					FUV56ZH0GB

DNA TOPOISOMERASE 1

TARGET -> INHIBITOR

Amount:

Related Record Type Details


					UJR3SD8NLS

Tizetatug Rezetecan

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO ACID REMOVAL	[1_451] [2_451]	C-TERMINUS	K	Amount:	LYSINE	K3Z4F929H6
AMINO_ACID_SUBSTITUTION	[1_1] [2_1]	N-TERMINUS	Q	Amount:	PIDOLIC ACID	SZB83O1W42
AMINO_ACID_SUBSTITUTION	[1_224] [1_230] [1_233] [2_224] [2_230] [2_233] [3_214] [4_214]	SITE_SPECIFIC	C	Amount:	UNSPECIFIED SUBSTANCE	a9e52966 (not in database)

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
Molecular Formula	CHEMICAL
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL